The socioeconomic burden of systemic lupus erythematosus: state-of-the-art and prospects

References

• Mageed RA, Prud’homme GJ. Immunopathology and the gene therapy of lupus. Gene Ther.10(10), 861–874 (2003).
   PubMed Web of Science ®Google Scholar
• Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus15(5), 308–318 (2006).
   PubMed Web of Science ®Google Scholar
• Feng PH. Systemic lupus erythematosus: the face of Asia. Ann. NY Acad. Sci.1108, 114–120 (2007).
   PubMed Web of Science ®Google Scholar
• D’Cruz DP, Khamashta MA, Hughes GR. Systemic lupus erythematosus. Lancet369(9561), 587–596 (2007).
   PubMed Web of Science ®Google Scholar
• Moore RA, Derry S. Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis. Arthritis Res. Ther.8(6), R182 (2006).
   PubMed Web of Science ®Google Scholar
• Wallace DJ, Stohl W, Furie RA et al. A Phase 2, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum.61(9), 1168–1178 (2009).
   PubMed Web of Science ®Google Scholar
• Rice DP. Estimating the cost of illness. Am. J. Public Health Nations Health57(3), 424–440 (1967).
   PubMed Web of Science ®Google Scholar
• Fautrel B, Guillemin F. Cost of illness studies in rheumatic diseases. Curr. Opin. Rheumatol.14(2), 121–126 (2002).
   PubMed Web of Science ®Google Scholar
• Hodgson TA, Meiners MR. Cost-of-illness methodology: a guide to current practices and procedures. Milbank Mem. Fund Q. Health Soc.60(3), 429–462 (1982).
   PubMedGoogle Scholar
• Merkesdal S, Ruof J, Huelsemann JL et al. Development of a matrix of cost domains in economic evaluation of rheumatoid arthritis. J. Rheumatol.28(3), 657–661 (2001).
   PubMed Web of Science ®Google Scholar
• Liljas B. How to calculate indirect costs in economic evaluations. Pharmacoeconomics13(1 Pt 1), 1–7 (1998).
   PubMed Web of Science ®Google Scholar
• van den Hout WB. The value of productivity: human-capital versus friction-cost method. Ann. Rheum. Dis.69(Suppl. 1), i89–i91 (2010).
   PubMed Web of Science ®Google Scholar
• Brouwer WB, Koopmanschap MA. The friction-cost method: replacement for nothing and leisure for free? Pharmacoeconomics23(2), 105–111 (2005).
   PubMed Web of Science ®Google Scholar
• Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a quality-adjusted life year: in search of a standard. Med. Decis. Making20(3), 332–342 (2000).
   PubMed Web of Science ®Google Scholar
• Koopmanschap MA, Rutten FF, van Ineveld BM, van Roijen L. The friction cost method for measuring indirect costs of disease. J. Health Econ.14(2), 171–189 (1995).
   PubMed Web of Science ®Google Scholar
• Diener A, O’Brien B, Gafni A. Health care contingent valuation studies: a review and classification of the literature. Health Econ.7(4), 313–326 (1998).
   PubMed Web of Science ®Google Scholar
• Tarricone R. Cost-of-illness analysis. What room in health economics? Health Policy77(1), 51–63 (2006).
   PubMed Web of Science ®Google Scholar
• Robinson JC. Philosophical origins of the economic valuation of life. Milbank Q.64(1), 133–155 (1986).
   PubMed Web of Science ®Google Scholar
• Akobundu E, Ju J, Blatt L, Mullins CD. Cost-of-illness studies: a review of current methods. Pharmacoeconomics24(9), 869–890 (2006).
   PubMed Web of Science ®Google Scholar
• Cooper NJ. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology39(1), 28–33 (2000).
   PubMed Web of Science ®Google Scholar
• Pugner KM, Scott DI, Holmes JW, Hieke K. The costs of rheumatoid arthritis: an international long-term view. Semin. Arthritis Rheum.29(5), 305–320 (2000).
   PubMed Web of Science ®Google Scholar
• Shiell A, Gerard K, Donaldson C. Cost of illness studies: an aid to decision making? Health Policy8, 317–323 (1987).
   Web of Science ®Google Scholar
• Hodgson TA. Cost of illness studies: no aid to decision making? Comments on the second opinion by Shiell et al.Health Policy8(1987), 317–323. Health Policy11(1), 57–60 (1989).
   Google Scholar
• Koopmanschap MA. Cost-of-illness studies. Useful for health policy? Pharmacoeconomics14(2), 143–148 (1998).
   PubMed Web of Science ®Google Scholar
• Rice DP. Cost of illness studies: what is good about them? Injury Prev.6(3), 177–179 (2000).
   PubMedGoogle Scholar
• Mooney G, Irwig L, Leeder S. Priority setting in health care: unburdening from the burden of disease. Aust. NZ J. Public Health21(7), 680–681 (1997).
   PubMed Web of Science ®Google Scholar
• Mooney G, Wiseman V. Burden of disease and priority setting. Health Econ.9(5), 369–372 (2000).
   PubMed Web of Science ®Google Scholar
• Drummond M. Cost-of-illness studies: a major headache? Pharmacoeconomics2(1), 1–4 (1992).
   PubMedGoogle Scholar
• Gabriel S, Drummond M, Suarez-Almazor ME et al. OMERACT 5 Economics Working Group: summary, recommendations, and research agenda. J. Rheumatol.28(3), 670–673 (2001).
   PubMedGoogle Scholar
• Rice DP. Cost-of-illness studies: fact or fiction? Lancet344(8936), 1519–1520 (1994).
   PubMed Web of Science ®Google Scholar
• Rice DP, MacKenzie EJ, Jones AS et al.Cost of Injury in the United States: A Report to Congress. Institute for Health and Aging, University of California and Injury Prevention Center, Johns Hopkins University, CA, USA (1989).
   Google Scholar
• Miller LS, Zhang X, Novotny T, Rice DP, Max W. State estimates of medicaid expenditures attributable to cigarette smoking, fiscal year 1993. Public Health Rep.113(2), 140–151 (1998).
   PubMedGoogle Scholar
• Fleming MF, Mundt MP, French MT et al. Benefit-cost analysis of brief physician advice with problem drinkers in primary care settings. Med. Care38(1), 7–18 (2000).
   PubMed Web of Science ®Google Scholar
• French MT, Martin RF. The costs of drug abuse consequences: a summary of research findings. J. Subst. Abuse Treat.13(6), 453–466 (1996).
   PubMed Web of Science ®Google Scholar
• Clarke AE, Petri M, Manzi S et al. The systemic lupus erythematosus Tri-Nation Study: absence of a link between health resource use and health outcome. Rheumatology43(8), 1016–1024 (2004).
   PubMed Web of Science ®Google Scholar
• Gironimi G, Clarke AE, Hamilton VH et al. Why health care costs more in the USA: comparing health care expenditures between systemic lupus erythematosus patients in Stanford and Montreal. Arthritis Rheum.39(6), 979–987 (1996).
   PubMedGoogle Scholar
• Aghdassi E, Zhang W, St-Pierre Y et al. Healthcare cost and loss of productivity in a Canadian population of patients with and without lupus nephritis. J. Rheumatol.38(4), 658–666 (2011).
   PubMedGoogle Scholar
• Clarke AE, Esdaile JM, Bloch DA et al. A Canadian study of the total medical costs for patients with systemic lupus erythematosus and the predictors of costs. Arthritis Rheum.36(11), 1548–1559 (1993).
   PubMedGoogle Scholar
• Clarke AE, Penrod J, St Pierre Y et al. Underestimating the value of women: assessing the indirect costs of women with systemic lupus erythematosus. Tri-Nation study group. J. Rheumatol.27(11), 2597–2604 (2000).
   PubMedGoogle Scholar
• Clarke AE, Petri MA, Manzi S et al. An international perspective on the well being and health care costs for patients with systemic lupus erythematosus. Tri-Nation study group. J. Rheumatol.26(7), 1500–1511 (1999).
   PubMed Web of Science ®Google Scholar
• Panopalis P, Petri M, Manzi S et al. The systemic lupus erythematosus Tri-Nation study: cumulative indirect costs. Arthritis Rheum.57(1), 64–70 (2007).
   PubMed Web of Science ®Google Scholar
• Panopalis P, Yazdany J, Gillis JZ et al. Health care costs and costs associated with changes in work productivity among persons with systemic lupus erythematosus. Arthritis Rheum.59(12), 1788–1795 (2008).
   PubMedGoogle Scholar
• Sutcliffe N, Clarke AE, Taylor R, Frost C, Isenberg DA. Total costs and predictors of costs in patients with systemic lupus erythematosus. Rheumatology40(1), 37–47 (2001).
   PubMed Web of Science ®Google Scholar
• Zhu TY, Tam LS, Lee VW, Lee KK, Li EK. Systemic lupus erythematosus with neuropsychiatric manifestation incurs high disease costs: a cost-of-illness study in Hong Kong. Rheumatology48(5), 564–568 (2009).
   PubMedGoogle Scholar
• Brunner HI, Sherrard TM, Klein-Gitelman MS. Cost of treatment of childhood-onset systemic lupus erythematosus. Arthritis Rheum.55(2), 184–188 (2006).
   PubMedGoogle Scholar
• Huscher D, Merkesdal S, Thiele K et al. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann. Rheum. Dis.65(9), 1175–1183 (2006).
   PubMed Web of Science ®Google Scholar
• Li T, Carls GS, Panopalis P et al. Long-term medical costs and resource utilization in systemic lupus erythematosus and lupus nephritis: a five-year analysis of a large medicaid population. Arthritis Rheum.61(6), 755–763 (2009).
   PubMedGoogle Scholar
• Carls G, Li T, Panopalis P et al. Direct and indirect costs to employers of patients with systemic lupus erythematosus with and without nephritis. J. Occup. Environ. Med.51(1), 66–79 (2009).
   PubMed Web of Science ®Google Scholar
• Pelletier EM, Ogale S, Yu E, Brunetta P, Garg J. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database. Clin. Ther.31(11), 2653–2664 (2009).
   PubMed Web of Science ®Google Scholar
• Chiu YM, Lai CH. Nationwide population-based epidemiologic study of systemic lupus erythematosus in Taiwan. Lupus19(10), 1250–1255 (2010).
   PubMedGoogle Scholar
• Zhu TY, Tam LS, Lee VW, Lee KK, Li EK. The impact of flare on disease costs of patients with systemic lupus erythematosus. Arthritis Rheum.61(9), 1159–1167 (2009).
   PubMedGoogle Scholar
• Baker K, Pope J. Employment and work disability in systemic lupus erythematosus: a systematic review. Rheumatology48(3), 281–284 (2009).
   PubMed Web of Science ®Google Scholar
• Yelin E, Trupin L, Katz P et al. Work dynamics among persons with systemic lupus erythematosus. Arthritis Rheum.57, 56–63 (2007).
   PubMed Web of Science ®Google Scholar
• Gordon C, Clarke AE. Quality of life and economic evaluation in SLE clinical trials. Lupus8(8), 645–654 (1999).
   PubMedGoogle Scholar
• Petri M, Genovese M, Engle E, Hochberg M. Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study. Arthritis Rheum.34(8), 937–944 (1991).
   PubMed Web of Science ®Google Scholar
• Urowitz MB, Feletar M, Bruce IN, Ibanez D, Gladman DD. Prolonged remission in systemic lupus erythematosus. J. Rheumatol.32(8), 1467–1472 (2005).
   PubMed Web of Science ®Google Scholar
• Klein-Gitelman M, Reiff A, Silverman ED. Systemic lupus erythematosus in childhood. Rheum. Dis. Clin. N. Am.28(3), 561–577, vi–vii (2002).
   PubMed Web of Science ®Google Scholar
• Brunner HI, Gladman DD, Ibanez D, Urowitz MD, Silverman ED. Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum.58(2), 556–562 (2008).
   PubMed Web of Science ®Google Scholar
• Lacaille D, Clarke AE, Bloch DA, Danoff D, Esdaile JM. The impact of disease activity, treatment and disease severity on short-term costs of systemic lupus erythematosus. J. Rheumatol.21(3), 448–453 (1994).
   PubMedGoogle Scholar
• Clarke AE, Panopalis P, Petri M et al. SLE patients with renal damage incur higher health care costs. Rheumatology (Oxf.)47(3), 329–333 (2008).
   PubMed Web of Science ®Google Scholar
• Hanly JG, Urowitz MB, Sanchez-Guerrero J et al. Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum.56(1), 265–273 (2007).
   PubMed Web of Science ®Google Scholar
• Jonsen A, Bengtsson AA, Nived O, Ryberg B, Sturfelt G. Outcome of neuropsychiatric systemic lupus erythematosus within a defined Swedish population: increased morbidity but low mortality. Rheumatology41(11), 1308–1312 (2002).
   PubMed Web of Science ®Google Scholar
• Utset TO, Fink J, Doninger NA. Prevalence of neurocognitive dysfunction and other clinical manifestations in disabled patients with systemic lupus erythematosus. J. Rheumatol.33(3), 531–538 (2006).
   PubMed Web of Science ®Google Scholar
• Petri M. Disease activity assessment in SLE: do we have the right instruments? Ann. Rheum. Dis.66(Suppl. 3), iii61–iii64 (2007).
   PubMedGoogle Scholar
• Durand-Zaleski I. Why cost-of-illness studies are important and inform policy. Vasc. Med.13(3), 251–253 (2008).
   PubMed Web of Science ®Google Scholar
• Weissman JS, Gatsonis C, Epstein AM. Rates of avoidable hospitalization by insurance status in Massachusetts and Maryland. JAMA268(17), 2388–2394 (1992).
   PubMed Web of Science ®Google Scholar
• Ward MM. Avoidable hospitalizations in patients with systemic lupus erythematosus. Arthritis Rheum.59(2), 162–168 (2008).
   PubMedGoogle Scholar
• Smith RM, Clatworthy MR, Jayne DR. Biological therapy for lupus nephritis-tribulations and trials. Nat. Rev. Rheumatol.6(9), 547–552 (2010).
   PubMedGoogle Scholar
• Hahn BH. Targeted therapies in systemic lupus erythematosus: successes, failures and future. Ann. Rheum. Dis.70(Suppl. 1), i64–i66 (2011).
   PubMed Web of Science ®Google Scholar
• Navarra SV, Guzman RM, Gallacher AE et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, Phase 3 trial. Lancet377(9767), 721–731 (2011).
   PubMed Web of Science ®Google Scholar
• Zhang W, Koehoorn M, Anis AH. Work productivity among employed Canadians with arthritis. J. Occup. Environ. Med.52(9), 872–877 (2010).
   PubMedGoogle Scholar
• Gignac MA, Badley EM, Lacaille D et al. Managing arthritis and employment: making arthritis-related work changes as a means of adaptation. Arthritis Rheum.51(6), 909–916 (2004).
   PubMedGoogle Scholar
• Wolfe F, Michaud K. Out-of-pocket expenses and their burden in patients with rheumatoid arthritis. Arthritis Rheum.61(11), 1563–1570 (2009).
   PubMedGoogle Scholar
• Hulsemann JL, Mittendorf T, Merkesdal S et al. Direct costs related to rheumatoid arthritis: the patient perspective. Ann. Rheum. Dis.64(10), 1456–1461 (2005).
   PubMed Web of Science ®Google Scholar
• Zhu TY, Tam LS, Li EK. Cost of illness studies in systemic lupus erythematosus: a systematic review. Arthritis Care Res.63(5), 751–760 (2011).
   PubMed Web of Science ®Google Scholar